VANCOUVER, BC, March 19, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for…
U.S. drug shortages have reached a decade high and are lasting longer, too
Amid rising concern over prescription drug shortages, a new report finds that the number of shortages has increased over the past decade, most are lasting
June 4, 2024